Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/27409
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSchippling, S.-
dc.contributor.authorArnold, D.-
dc.contributor.authorBarnett, M.-
dc.contributor.authorComi, G.-
dc.contributor.authorLaganke, C.-
dc.contributor.authorRovira, A.-
dc.contributor.authorTraboulsee, A.-
dc.contributor.authorMelanson, M.-
dc.contributor.authorDaizadeh, N.-
dc.contributor.authorNakamura, K.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorPelletier, D.-
dc.date.accessioned2018-11-15T13:56:08Z-
dc.date.available2018-11-15T13:56:08Z-
dc.date.issued2018-
dc.identifier.citationEUROPEAN JOURNAL OF NEUROLOGY, 25(S2), p. 527-527 (Art N° EPR3087)-
dc.identifier.issn1351-5101-
dc.identifier.urihttp://hdl.handle.net/1942/27409-
dc.description.sponsorshipSanofi; Bayer HealthCare Pharmaceuticals-
dc.language.isoen-
dc.publisherWILEY-
dc.titleDurable suppression of MRI disease activity and slowing of brain volume loss in alemtuzumab-treated patients with active RRMS: 7-year follow-up of CARE-MS I (TOPAZ Study)-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateJUN 16-19, 2018-
local.bibliographicCitation.conferencename4th Congress of the European-Academy-of-Neurology (EAN)-
local.bibliographicCitation.conferenceplaceLisbon, PORTUGAL-
dc.identifier.epage527-
dc.identifier.issueS2-
dc.identifier.spage527-
dc.identifier.volume25-
local.format.pages1-
local.bibliographicCitation.jcatM-
dc.description.notes[Schippling, S.] Univ Hosp Zurich, Neuroimmunol & Multiple Sclerosis Res, Zurich, Switzerland. [Schippling, S.] Univ Zurich, Zurich, Switzerland. [Arnold, D.] NeuroRx Res, Montreal, PQ, Canada. [Arnold, D.] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada. [Barnett, M.] Univ Sydney, Sydney, NSW, Australia. [Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy. [Laganke, C.] North Cent Neurol Associates, Cullman, AL USA. [Rovira, A.] Vall dHebron Univ Hosp, Barcelona, Spain. [Traboulsee, A.] Univ British Columbia, Vancouver, BC, Canada. [Melanson, M.; Daizadeh, N.; OBOTC-MIC Investigator; Topaz Investigator] Sanofi, Cambridge, MA USA. [Nakamura, K.] Cleveland Clin, Cleveland, OH 44106 USA. [van Wijmeersch, B.] Hasselt Univ, Hasselt, Belgium. [Pelletier, D.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA.-
local.publisher.placeHOBOKEN-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnrEPR3087-
dc.identifier.isi000435272002408-
item.accessRightsOpen Access-
item.fulltextWith Fulltext-
item.contributorSchippling, S.-
item.contributorArnold, D.-
item.contributorBarnett, M.-
item.contributorComi, G.-
item.contributorLaganke, C.-
item.contributorRovira, A.-
item.contributorTraboulsee, A.-
item.contributorMelanson, M.-
item.contributorDaizadeh, N.-
item.contributorNakamura, K.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorPelletier, D.-
item.fullcitationSchippling, S.; Arnold, D.; Barnett, M.; Comi, G.; Laganke, C.; Rovira, A.; Traboulsee, A.; Melanson, M.; Daizadeh, N.; Nakamura, K.; VAN WIJMEERSCH, Bart & Pelletier, D. (2018) Durable suppression of MRI disease activity and slowing of brain volume loss in alemtuzumab-treated patients with active RRMS: 7-year follow-up of CARE-MS I (TOPAZ Study). In: EUROPEAN JOURNAL OF NEUROLOGY, 25(S2), p. 527-527 (Art N° EPR3087).-
crisitem.journal.issn1351-5101-
crisitem.journal.eissn1468-1331-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
p 527 2018-European_Journal_of_Neurology.pdfPublished version104.31 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.